Tyramine Ingestion and Migraine Attack: A Systematic Review

Harvey Sudharta, Octavianus Darmawan, Jimmy F. A. Barus

Department of Neurology, School of Medicine and Health Science, Atma Jaya Catholic University of Indonesia, Atma Jaya Neuroscience and Cognitive Center, Jakarta, Indonesia

Abstract

AIM: This systematic review aimed to clarify the association between tyramine ingestion (food/capsule) with the occurrence of a migraine attack.

METHODS: Based on a comprehensive search of PubMed, PMC, ProQuest, and EBSCOhost, we included all studies that observed migraine headaches after tyramine ingestion. Association was evaluated with the control (placebo) group as a comparison. We further assessed the abstracts and full texts of selected papers. We included articles fulfilling the inclusion criteria in this systematic review.

RESULTS: Seven non-randomized studies with 322 eligible subjects (168 women, 63 men, and 91 unknown genders) aged 4 to 62 years old were included in the study. A high to moderate (17.2–50%) occurrence of headache after tyramine ingestion was observed. Similar results were observed in the control (placebo) group (0–42.1%). Quality appraisal on all seven non-randomized studies using ROBINS-I showed that six studies had a moderate risk of bias, and one study had a serious risk of bias.

CONCLUSION: The relationship between tyramine-containing food and migraine remains unclear.

Introduction

Headache is one of the most prevalent neurological disorders and the most frequent symptom seen in general practice [1]. The two most common primary headache subtypes are tension-type headache (TTH) and migraine [2]. More than 90% of the general population worldwide reported a lifetime history of headaches [3]. Migraine is a disabling chronic disease that influences an individual physical, mental, and social function. The active global prevalence of migraine is 10–15%. It is commonly found between the ages 25–55 years, which is a productive age, meaning that it will cause a significant economic impact if left untreated. Migraine is also 3 times more common in females [4].

Many factors contributed to the onset, frequency, duration, and severity of migraine attacks, including nutrition as a predisposing factor or even as a trigger [5]. For years, tyramine has been associated with migraine attacks. Tyramine is a trace monoamine produced in foods from the natural breakdown of the amino acid tyrosine. Monoamines (such as dopamine, norepinephrine, and serotonin) are molecules with an amine group separated from an aromatic ring by a two-carbon chain. It is naturally found in food, plants, and animals, but the levels will increase naturally when they are aged, fermented, stored for long periods, or when they are no longer fresh [6]. Tyramine is degraded by several enzymes, like decarboxylase enzyme [7]. Tyramine has long been shown to cause cardiovascular effects when consumed in large amounts or combined with monoamine oxidase inhibitors (MAOIs) [7]. It acts as a vasoactive amine that leads to cerebral vasoconstriction and subsequent rebound vasodilatation that causes a migraine attack in susceptible person [6].

Direct administration of tyramine displaces norepinephrine, epinephrine, and dopamine from presynaptic storage vesicles [9]. The release of these neurotransmitters, particularly norepinephrine, causes vasoconstriction, increased heart rate, and increased blood pressure. Tyramine causes the release of endogenous presynaptic neurotransmitters and disrupts the monoamine activity, further limiting the breakdown of monoamine neurotransmitters [10].

In this review, we aim to elucidate the role of tyramine as a risk factor for the development of migraine. Our study could provide additional insight into preventing migraine, primarily through nutrition.
Methods

For this systematic review, a structured literature search was conducted from inception until September 19, 2022, to identify published articles on the effect of tyramine ingestion on a migraine attack. We used the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement guideline, with a pre-determined search strategy, in which we identified potential studies, screened titles and abstracts, assessed full-text articles, and determined relevant studies.

Search strategy and selection criteria

We did a systematic literature search on PubMed, PMC, ProQuest, and EBSCOhost. The following search terms were used: (“tyramine” OR “4-hydroxyphenethylamine” OR “4 hydroxyphenethylamine”) AND (“migraine” OR “headache”). Table 1 provides our complete search terms strategy and findings. The search terms, especially for headaches, were kept broad to encompass all possibilities for applicable studies. There were no restrictions on the publication date and the articles’ language. After eliminating duplicates, the authors reviewed all titles and abstracts and excluded those articles with full text that failed to be retrieved. Any disagreement will be resolved with consensus.

<table>
<thead>
<tr>
<th>Source</th>
<th>Search term</th>
<th>Number of studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>(“Tyramine”[MeSH Terms] OR “Tyramine”[All Fields]) OR ’4' Hydroxyphenethylamine'[All Fields] OR ’4 hydroxyphenethylamine’ studies</td>
<td>194</td>
</tr>
<tr>
<td></td>
<td>Hydroxyphenethylamine[All Fields] AND (’Migraine'[MeSH Terms] OR “Migraine”[All Fields] OR ’Headache'[All Fields])</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(“Tyramine”[MeSH Terms] OR “Tyramine”[All Fields]) OR ’4' Hydroxyphenethylamine'[All Fields] OR ’4 hydroxyphenethylamine’ studies</td>
<td>698</td>
</tr>
<tr>
<td>PMC</td>
<td>(ti (“Tyramine”) OR ti (”4-hydroxyphenethylamine”) OR ti (“4'-hydroxyphenethylamine”) OR ti (”4'hydroxyphenethylamine”) AND (ti (”Migraine”) OR ti (”Headache”)) OR ab (”4'-hydroxyphenethylamine”) OR ab (”4'hydroxyphenethylamine”)</td>
<td>29 studies</td>
</tr>
<tr>
<td>ProQuest</td>
<td>(ti (“Tyramine”) OR ti (”4-hydroxyphenethylamine”) OR ti (”4'-hydroxyphenethylamine”) OR ti (”Migraine”) OR ti (”Headache”) AND (ti (”Migraine”) OR ti (”Headache”) OR ab ((”Migraine”) OR ab (”Headache”))</td>
<td>151 studies</td>
</tr>
<tr>
<td>EBSCOhost</td>
<td>(ti Migraine OR ti Headache OR ab Migraine OR ab ’4' hydroxyphenethylamine’) AND (ti (”Migraine”) OR ti (”Headache”)</td>
<td>151 studies</td>
</tr>
</tbody>
</table>

Inclusion and exclusion criteria

The inclusion criteria were the following: (a) clinical studies in humans, (b) diagnosis of migraine was clearly defined, (c) migraine was evaluated after ingestion of tyramine in chocolate/tyramine capsule, and (d) patients treated with placebo and/or any supplemental or non-invasive therapy as a comparison. The exclusion criteria were the following: (a) other types of studies, including case–control, cohort, cross-sectional, case report, case series, literature review, book sections, conference papers, preliminary report, and correspondences, (b) studies in animal subjects, (c) absence of a comparison group/placebo, (d) prior consumption of medication that affects platelet function/monoamine oxidase (MAO) activity, and (e) subjects with comorbidities.

Data extraction and analysis

We reviewed the final articles to extract the information from each: first author, date published; study design; study population characteristics; the number of samples; intervention; outcome measurement; and the result. The specific outcome measures recorded for the systematic review were the frequency of headache/migraine attacks ≤48 h after the ingestion of tyramine. The information was extracted by two independent authors (HS and OD) to ensure the accuracy of all the data. We resolved all conflicting data with consensus among all the authors.

Quality assessment

Articles selected for the final analysis were graded by two authors (HS and OD) using Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) [11] for the quality assessment. We will resolve any disagreement with consensus. ROBINS-I is a tool for evaluating the risk of bias in estimates of the comparative effectiveness of interventions from studies that did not use randomization to allocate units to comparison groups [11]. This tool was deemed suitable as all five studies included in this study are non-randomized. All researchers independently evaluate the quality of each study, with any discrepancies resolved through consensus.

Result

Study selection

We identified 1077 published papers, and seven studies were included in this systematic review [12], [13], [14], [15], [16], [17], [18]. We imported results into Endnote X9 (Trial Version). From the initial search, a total of 199 articles were identified from PubMed, 698 from PMC database, 151 from EBSCOhost database, and 29 from ProQuest database. One hundred and ninety-three articles were excluded as duplicates, leaving 884 articles to be reviewed. The abstract of these articles was reviewed based on the following criteria: relevant independent and dependent variables, direct ingestion of tyramine or food-containing tyramine, and trial studies. Fourteen full texts were reviewed of which seven articles were excluded. Two of these excluded articles measure tyramine level in the case and control groups, one article measure tyramine...
in the food, one article measure tyramine excreted from the urine, one article uses blood pressure as the dependent variable, one article is only available in German language, and the last article only had a single subject. The search strategy and selection methods of the present study following PRISMA guidelines are illustrated in Figure 1.

Figure 1: Study selection process

We finally selected seven articles for the systematic review with the following criteria: clinical trial studies in humans, intervention in the form of tyramine supplementation, and headache/migraine attacks frequency are recorded completely. The study type, sample size, mean/median age, and male: female distribution of various studies are shown in Table 2. The group, intervention, measurement, and outcome are shown in Table 3.

**Study characteristics and demographics**

Table 2 shows the summary of all seven studies’ characteristics. All studies were considered old because they were done before 2000. A total of 322 subjects were collected; of all 231 subjects with identified gender, most were female (168/231; 72.7%).

The study population age varies from 4 to 62 years old. The range is considered wide because one study by Forsythe et al. [15] was conducted in children with an average age of 10.5 years (phase 1) and 9.6 years (phase 2), while the other four studies [13], [14], [17], [18] were conducted in adults. Two studies [12], [16] did not specify their study population characteristics.

Table 4 summarizes the intervention and the outcome of all studies. The intervention of tyramine ingestion was given in chocolate or capsule form. Three studies [13], [17], [18] use chocolate as a tyramine source compared to non-cocoa chocolate as a placebo. Four studies [12], [14], [15], [16] directly use tyramine powder in capsule form. The tyramine-containing chocolates used across all studies using chocolate were manufactured either by the American Cocoa Research Institute or Cadbury Ltd., Bournville, Birmingham. The dose of tyramine in tyramine-containing chocolates was not specified in any of the studies, but in the capsule form, the tyramine was given as much as 100 mg up to 250 mg daily.

Out of the ten experimental phases from seven studies, migraine attack from tyramine digestion (capsules/tyramine-containing chocolate) was low to moderate (17.2–50%), similar to placebo (0–42.1%). The definition of migraine varied across all studies, depending on the guidelines used then. All studies measured headaches <48 h after ingestion. Most post-ingestion headaches in these studies are identified as a migraine as it was reported to be similar to the patient’s usual migraine headache as described earlier by the patient questionnaire, except for one study by Moffett et al. in 1972 that described reported atypical headache compared to the patient’s usual migraine headaches.

**Quality appraisal**

Quality appraisal on all seven studies was done using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. Most of these studies showed moderate confounding bias as they are non-randomized and lacked patient dietary control before the intervention. This is an essential factor in this study observing the association between tyramine-containing food and migraine attack. The study by Forsythe
et al. [15] also told the parents about the contents of the capsule; therefore, this might affect the outcome psychologically. One study by Marcus et al. [18] was considered a low confounding bias because they restricted vasoactive amine consumption 2 weeks before the intervention, and subjects were asked to fill in food diaries for diet monitoring. Two studies by Hanington et al. [12] and Ryan et al. [16] did not specify their study population characteristics/demographics (e.g., age, female-to-male ratio, and recent drug use); therefore, the author considered this a risk for confounding and selection bias.

The measurement of the outcomes of all studies was considered prone to bias because they are based on subjective feelings of headache and thus cannot be scientifically proven. However, the authors of this study believe that migraine attacks are subjective bodily symptoms. Thus, they are difficult to measure objectively.

### Discussion

Many of the subjects in these studies (72.7%) were female. The reason is that migraine is a predominantly female disorder and most reports of foods triggering headaches also came from women [19]. The age of the included studies ranged from 4 to 62 years. Migraine is a common disease in childhood, with its highest prevalence in adolescence and early adulthood.

---

Table 3: Summary of risk of bias in nonrandomized studies of interventions - I assessment

<table>
<thead>
<tr>
<th>Author</th>
<th>Confounding bias</th>
<th>Selection bias</th>
<th>Measurement of intervention</th>
<th>Deviation from intended intervention</th>
<th>Missing data</th>
<th>Measurement of outcomes</th>
<th>Reported result</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanington, (1967)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>High</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Low</td>
<td>Moderate</td>
</tr>
<tr>
<td>Moffett et al., (1972)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Forsythe et al., (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td>Gibb et al., (1991)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Marcus et al., (1997)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>

Table 4: Interventions and measured outcomes

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Group</th>
<th>Intervention</th>
<th>Assessment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanington (1967)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (capsule)</td>
<td>12 subjects were given a capsule containing 100 mg of tyramine</td>
<td>Headache after ingestion of a capsule in 24 h</td>
<td>6 subjects (55.0%) had headache after tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>12 of the same subjects were given a capsule containing 100 mg of lactose as placebo</td>
<td></td>
<td>6 subjects (9.4%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Moffett et al. (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (chocolate)</td>
<td>25 subjects were given 44–62 g of chocolate containing tyramine</td>
<td>Headache after ingestion of a chocolate sample in 48 h</td>
<td>6 subjects (40.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>25 of the same subjects were given 44–62 g of placebo (nancocoa and coberine-containing chocolate), 14 days after chocolate ingestion</td>
<td></td>
<td>6 subjects (40.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Forsythe et al. (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (chocolate)</td>
<td>15 subjects from the first trial were given 44–62 g of chocolate containing tyramine</td>
<td>Headache after ingestion of a chocolate sample in 48 h</td>
<td>4 subjects (27.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>15 subjects from the first trial were given 44–62 g of placebo (nancocoa and coberine-containing chocolate), 14 days after chocolate ingestion</td>
<td></td>
<td>4 subjects (27.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Forsythe et al. (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (capsule)</td>
<td>25 subjects were given a capsule containing 125mg of tyramine</td>
<td>Headache after ingestion of a capsule in 48 h</td>
<td>6 subjects (24.0%) had headache after tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>25 of the same subjects were given a capsule containing 125 mg of lactose placebo, 4–7 days after chocolate ingestion</td>
<td></td>
<td>6 subjects (24.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Ryan et al. (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (chocolate)</td>
<td>59 subjects were given a capsule containing 100 mg of tyramine</td>
<td>Headache after ingestion of a capsule in 48 h</td>
<td>16 subjects (27.1%) had headache after tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>59 subjects were given a capsule containing 100 mg of lactose placebo, 2 days after chocolate ingestion</td>
<td></td>
<td>14 subjects (23.7%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Ryan et al. (1974)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (capsule)</td>
<td>38 subjects were given a capsule containing 100 mg of tyramine</td>
<td>Headache after ingestion of a capsule in 48 h</td>
<td>9 subjects (23.7%) had headache after tyramine consumption (5 after tyramine only, 4 after both tyramine and placebo)</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>38 of the same subjects were given a capsule containing 100 mg of lactose placebo, 2 days after chocolate ingestion</td>
<td></td>
<td>16 subjects (42.1%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Ryan et al. (1994)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (capsule)</td>
<td>79 subjects were given a capsule containing 125 mg of tyramine</td>
<td>Headache after ingestion of a capsule in 24 h</td>
<td>11 subjects (35.9%) had headache after tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>79 of the same subjects were given a capsule containing unspecified placebo, 24 h after chocolate ingestion</td>
<td></td>
<td>33 subjects (41.8%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Ryan et al. (1994)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (capsule)</td>
<td>50 subjects were given a capsule containing 125 mg of tyramine</td>
<td>Headache after ingestion of a capsule in 24 h</td>
<td>17 subjects (34.0%) had headache after tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>23 subjects were given a capsule containing 250 mg of tyramine</td>
<td></td>
<td>5 subjects (21.7%) had headache after higher dose tyramine consumption</td>
</tr>
<tr>
<td></td>
<td>Higher dose Tyramine (capsule)</td>
<td>73 subjects were given a capsule containing unspecified placebo, 24 h after chocolate ingestion</td>
<td></td>
<td>26 subjects (35.6%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Gibb CM et al. (1991)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (chocolate)</td>
<td>12 subjects were given 40 g of bar chocolate</td>
<td>Headache after ingestion of a chocolate sample in 32 h</td>
<td>5 subjects (41.1%) had headache after chocolate consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>8 subjects were given 40 g of placebo (nancocoa and coberine-containing chocolate)</td>
<td></td>
<td>11 subjects (63.0%) had headache after placebo consumption</td>
</tr>
<tr>
<td>Marcus et al. (1997)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Tyramine (chocolate)</td>
<td>64 subjects were given 60 g of bar chocolate</td>
<td>Headache after ingestion of a chocolate sample in 12 h</td>
<td>26 subjects (46.8%) had headache after placebo consumption</td>
</tr>
<tr>
<td></td>
<td>Control (placebo)</td>
<td>64 of the same subjects were given 60g of placebo (nancocoa and coberine-containing chocolate)</td>
<td></td>
<td>26 subjects (40.3%) had headache after placebo consumption</td>
</tr>
</tbody>
</table>

<sup>12</sup>Subjects participation gin phase-2 trials who were kept from phase-1 trial, <sup>13</sup>Completely new subjects who have not participated in phase-1 trial.
(late teens and early twenties). In children, headaches are considered rare, especially in children below the age of 4, because the data collection in this population was challenging [20], [21]. Migraine was common in late adolescence and early adulthood, with the prevalence peaking in late teens and early 20s [22].

The association between chocolate and migraine attack is rather ambiguous. The original evidence of an association between chocolate and migraine attack was based on the assumption of allergy mechanism. However, epidemiologic surveys showed controversial results. A study by Peatfield surveys [23] reported that migraine attributed to chocolate in 19% of subjects, higher compared to other non-tyramine food (e.g., citrus 11%; p < 0.001), but still lower than that of alcohol (29%; p < 0.001) and oral contraceptives in females (31%; p < 0.001). A study by Van den Bergh et al. on 217 migraineurs showed that chocolate caused migraine attacks in 22.5% of cases, still lower than alcoholic beverages (51.6%) but higher than cheese and dairy products (18.5%). In comparison, several other studies reported that the headache was attributable to chocolate in only 1.4 to 1.7% of cases [24], [25], [26], [27], this number was far lower than what was reported previously. A study by Yadav et al. [28] in 182 patients reported that no migraine attacks could likely be attributable to chocolate.

Hanington first postulated the potential association between tyramine-containing food and migraine attacks in 1967 [12]. A remarkable proportion of migraine sufferers had attributed their headaches to the consumption of certain types of food including cheese, citrus, chocolate, and alcohol. Many agreed that alcoholic beverages were most likely to trigger migraine attacks, followed by chocolate, cheese, and dairy products in order [29], [30], [31]. The difference in tyramine dose across food and beverages may explain this result because tyramine acts on the adipose tissues in a dose-dependent antilipolytic effect. A dose of 10 mg tyramine has been associated with a migraine attack, with a lower dose of 6 mg if monoamine oxidase inhibitor (MAOI) was consumed before tyramine ingestion. A high-performance liquid-chromatography study showed most beers contain roughly 0–3.16 mg/L of tyramine [32], which is far higher than chocolate (0.1–2.8 mcg/g of tyramine) [33], [34], and cheese (depending on the type of cheese but in general 17.5 ± 6.1 mcg/g of tyramine) [35]. Besides, Littlewood et al. [36] also showed that some alcoholic beverages like red wines might contain a migraine-provoking agent that is neither alcohol nor tyramine.

Many individual and dietary factors along with various mechanisms may contribute to the development of migraine, from neuropeptides, neureceptors, ion channels, sympathetic nervous system, cerebral glucose metabolism, inflammation pathway, nitric oxide release, etc. There was a belief that tyramine only induced migraine in previously migrainous patients, postulated a low concentration of gut monoamine oxidase in this population. A study by Smith et al. [37] observed tyramine excretion in urine after tyramine ingestion opposed this hypothesis. The result showed a similar level of free p-hydroxy-phenylacetic-acid (HPAA) in the urine of both normal and migrainous patients, meaning both populations have similar monoamine oxidase concentrations and aldehyde oxidase in the liver, kidney, and gut.

The limitations of this study are: (1) All of the studies recorded are considered old studies, and the author could not identify additional studies that could conclusively elucidate this hypothesis. More research is needed in a larger controlled sample size. (2) Many factors could contribute to migraine attacks. Thus, it is difficult for the researcher to control all confounding variables that might play a role. Most studies can only control the ingestion of medication that affects monoamine oxidase enzyme activity in their sample. (3) The inability to objectively measure migraine headaches as a subjective bodily symptom may affect the data recording.

Conclusion

The relationship between tyramine-containing food and migraine remains unclear. Patients with migraine should not completely avoid all of the food described in this study unless they obtain a clear association and consistent migraine attacks after certain food ingestion. Many individual and dietary factors, along with various mechanisms, may contribute to the development of migraine. The effects of dietary triggers also depended on dosage, the timing of exposure, and genetic factors. Further controlled large-population clinical trials with randomization are needed to draw a more conclusive result.

References

3. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents:
PMid:20875042

PMid:20352581

PMid:23833603

PMid:17971007

PMid:30255284


PMid:832672

PMid:2666453

PMid:27733354

PMid:5337268

PMid:4838915

PMid:4559027

PMid:4613591

PMid:4599015

PMid:1860135

PMid:9453274

PMid:219389

PMid:11348907

PMid:4042154

PMid:30967767

PMid:6498931

PMid:8951947

PMid:10759917

PMid:19705059

PMid:22042255

PMid:19793343

PMid:3597073

PMid:6498931

PMid:18613707


